• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Karyopharm - oncology

Quote
anonymous said:
There really wasn’t alternative. It’s a low volume, low revenue drug…not a lot of ROW partners where lining up to get a piece of the drug. What did you expect? Some major player coming in and dropping a big number on us?
Click to expand...

So it seems you agree with my point that this was a desperation move, I never implied that companies were lining up or that another player would "drop a big number". There are other options, such as a complete fire sale, but again for an approved asset, this deal approaches fire-sale levels.
 




anonymous said:
So it seems you agree with my point that this was a desperation move, I never implied that companies were lining up or that another player would "drop a big number". There are other options, such as a complete fire sale, but again for an approved asset, this deal approaches fire-sale levels.
Click to expand...

Not sure I agree that is was desperation. Just a standard practice for companies our size, with the revenue stream the drug creates, along with our cash on hand and no commercial footprint anywhere else in the world. The drug is low revenue low upside so it being an ‘approved asset’ doesn’t mean anything if said asset does not produce or look like it will produce substantial and sustainable revenue.

Not sure what sort of ‘fire sale’ you are implying. What other options would you have considered for scaling up commercialization and distribution in the ROW?
 








anonymous said:
Stock price down 33% in last six months. Happy New Year to Peter Principle Paulson!
Click to expand...


Not an RP fan at all but this isn’t on him. Look at MK for over hyping Seli early to the street, and it’s potential revenue stream…then actually revenue was seen and the stock landed at a FMV based on current revenue and speculative revenue. RP inherited a mess and I agree that he is not the guy to fix it but it’s a seldom used drug in a crowded market with a questionable tox profile. Endometrial will not be as big of a revenue generator as we think so if RP is banging that drum that will be on him. So far the street isn’t buying it…
 




anonymous said:
Not an RP fan at all but this isn’t on him. Look at MK for over hyping Seli early to the street, and it’s potential revenue stream…then actually revenue was seen and the stock landed at a FMV based on current revenue and speculative revenue. RP inherited a mess and I agree that he is not the guy to fix it but it’s a seldom used drug in a crowded market with a questionable tox profile. Endometrial will not be as big of a revenue generator as we think so if RP is banging that drum that will be on him. So far the street isn’t buying it…
Click to expand...

Sorry, this doesn’t get close to passing the smell test. It comes down to adulthood, leadership and accountability, things that Ricky knows virtually nothing about. He has no trouble taking credit for all successes under his watch, regardless of whether or not he had a damn thing to do with them. You break it, you bought it. He’s supposedly in charge. Everything that happens now lands at his feet. Or maybe they do things differently in Saskatchewan.
 




anonymous said:
Sorry, this doesn’t get close to passing the smell test. It comes down to adulthood, leadership and accountability, things that Ricky knows virtually nothing about. He has no trouble taking credit for all successes under his watch, regardless of whether or not he had a damn thing to do with them. You break it, you bought it. He’s supposedly in charge. Everything that happens now lands at his feet. Or maybe they do things differently in Saskatchewan.
Click to expand...


That’s pretty much what I said…he owns it now but he can’t be held accountable for things that impacted the share price before he got here. The share price decline was well on its way before he took the helm. Again not saying he is good it will be good what I’m saying is do not underestimate how awful MK was as our CEO…his terrible business acumen is still having a lasting negative effect on the company and the share price that isn’t going to improve quickly. What the share price to go up? Drive more revenue and control costs while developing new revenue streams through new indications. It’s not that complex.
 




anonymous said:
Not sure I agree that is was desperation. Just a standard practice for companies our size, with the revenue stream the drug creates, along with our cash on hand and no commercial footprint anywhere else in the world. The drug is low revenue low upside so it being an ‘approved asset’ doesn’t mean anything if said asset does not produce or look like it will produce substantial and sustainable revenue.

Not sure what sort of ‘fire sale’ you are implying. What other options would you have considered for scaling up commercialization and distribution in the ROW?
Click to expand...

I see your point, no desperation here, continue to market the drug in the US with lousy results and continue to take on water till the boats at the bottom. Or do a massive raise and launch a marketing organization in....yeah no, probably not. Net/Net, the right thing was done but there weren't a ton of options. We had better hope the upfront gets put to good use because there probably isn't going to be much coming in on the back end of this deal in milestones/royalties.
 




anonymous said:
That’s pretty much what I said…he owns it now but he can’t be held accountable for things that impacted the share price before he got here. The share price decline was well on its way before he took the helm. Again not saying he is good it will be good what I’m saying is do not underestimate how awful MK was as our CEO…his terrible business acumen is still having a lasting negative effect on the company and the share price that isn’t going to improve quickly. What the share price to go up? Drive more revenue and control costs while developing new revenue streams through new indications. It’s not that complex.
Click to expand...

All hail King Dick. Let’s agree to agree on that.
 




Stay away from medical affairs unless you choose to work under worst leadership in pharma. Inept, toxic, rude, dysfunctional VP that has zero EQ or leadership skill. Team leaving in droves because of her and she is proud of it. EG needs to go.
 








EG is a joke! Zero medical acumen. She is more of an insecure dictator than a leader. She doesn’t value experience unless it was acquired at Amgen.
Her recent medical leadership hires are inexperienced for the roles they have been bought in to do. Yup a lot of new Peter Principle leaders. The environment is becoming increasingly toxic with a lot of “yes” people being allowed into her “inner circle of trust” and anyone with opinions contrary to hers being demeaned and bullied. Experience medical affairs folk are leaving in droves because respect is lacking. Lets face facts, no one wants to work where they are not appreciated and respected. A strong medical team needs a strong leader and she does even come close to making the cut.
 




anonymous said:
EG is a joke! Zero medical acumen. She is more of an insecure dictator than a leader. She doesn’t value experience unless it was acquired at Amgen.
Her recent medical leadership hires are inexperienced for the roles they have been bought in to do. Yup a lot of new Peter Principle leaders. The environment is becoming increasingly toxic with a lot of “yes” people being allowed into her “inner circle of trust” and anyone with opinions contrary to hers being demeaned and bullied. Experience medical affairs folk are leaving in droves because respect is lacking. Lets face facts, no one wants to work where they are not appreciated and respected. A strong medical team needs a strong leader and she does even come close to making the cut.
Click to expand...

and the new CCO...has turned the company around in 6 months...

L.L. PPP.... ;-) Who's down with triple P?!
 




anonymous said:
and the new CCO...has turned the company around in 6 months...

L.L. PPP.... ;-) Who's down with triple P?!
Click to expand...


What a joke…we are no better today than we were before ‘they’ got here, yet CCO titles are being gifted. This place gets worse by the day. Keep brining in your hack managers and reps from Amgen. Guess one told them that Amgen reps and managers are the bottom of the barrel, least respected people in oncology.
 




anonymous said:
What a joke…we are no better today than we were before ‘they’ got here, yet CCO titles are being gifted. This place gets worse by the day. Keep brining in your hack managers and reps from Amgen. Guess one told them that Amgen reps and managers are the bottom of the barrel, least respected people in oncology.
Click to expand...

A significant portion of all the assholes in the biopharma industry have some connection to Amgen, including Peter Principle Paulson. It’s been confirmed by science.
 




anonymous said:
A significant portion of all the assholes in the biopharma industry have some connection to Amgen, including Peter Principle Paulson. It’s been confirmed by science.
Click to expand...


Not really. Amgen was primarily a supportive care company and very few good biotech’s looked to Amgen to pull sales reps. You are probably an exOnyx person so yes in that world they are close. I was a long time Genentech person and I don’t know anyone from Amgen…thankfully.
 








anonymous said:
EG is a joke! Zero medical acumen. She is more of an insecure dictator than a leader. She doesn’t value experience unless it was acquired at Amgen.
Her recent medical leadership hires are inexperienced for the roles they have been bought in to do. Yup a lot of new Peter Principle leaders. The environment is becoming increasingly toxic with a lot of “yes” people being allowed into her “inner circle of trust” and anyone with opinions contrary to hers being demeaned and bullied. Experience medical affairs folk are leaving in droves because respect is lacking. Lets face facts, no one wants to work where they are not appreciated and respected. A strong medical team needs a strong leader and she does even come close to making the cut.
Click to expand...
 
















Top Bottom
Back
Quote